HCA
CSTL icon

Harbor Capital Advisors’s Castle Biosciences CSTL Stock Holding History

Harbor Capital Advisors’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$757K Buy
31,748
+6,134
+24% +$137K 0.05% 427
2026
Q1 		$629K Buy
25,614
+12,182
+91% +$399K 0.05% 437
2025
Q4 		$523K Buy
13,432
+261
+2% +$8.41K 0.04% 472
2025
Q3 		$300K Sell
13,171
-7,228
-35% -$147K 0.02% 569
2025
Q2 		$417K Buy
20,399
+3,804
+23% +$70.4K 0.02% 547
2025
Q1 		$332K Sell
16,595
-101,905
-86% -$2.52M 0.02% 574
2024
Q4 		$3.16M Sell
118,500
-35,407
-23% -$1.08M 0.14% 207
2024
Q3 		$4.39M Buy
153,907
+15,200
+11% +$387K 0.19% 163
2024
Q2 		$3.02M Buy
138,707
+99,001
+249% +$2.21M 0.23% 127
2024
Q1 		$879K Buy
39,706
+27,754
+232% +$604K 0.11% 246
2023
Q4 		$258K Buy
11,952
+2,205
+23% +$38.8K 0.05% 334
2023
Q3 		$165K Sell
9,747
-4,517
-32% -$79K 0.04% 370
2023
Q2 		$196K Buy
+14,264
New +$289K 0.04% 366

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.79B AUM 30.56% 1-Year Est. Return
ACM
Advisors Capital Management Ridgewood, New Jersey $9.45B AUM 27.66% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Harbor Capital Advisors's CSTL Position: Q2 2026 in Review

Harbor Capital Advisors increased its Castle Biosciences (CSTL) stake by 24% in Q2 2026, buying an estimated $137K and bringing the position to 31,748 shares worth $757K. The position accounts for 0.05% of the portfolio, ranked #427.

Harbor Capital Advisors first reported a position in CSTL in Q2 2023 and has held it in 13 quarters since. The position peaked at $4.39M in Q3 2024. 77 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Harbor Capital Advisors held 31,748 shares of Castle Biosciences worth $757K as of Q2 2026.
  • Harbor Capital Advisors bought 6,134 Castle Biosciences shares in Q2 2026, an estimated $137K.
  • Castle Biosciences made up 0.05% of Harbor Capital Advisors's portfolio in Q2 2026, its #427 holding.
  • Harbor Capital Advisors first reported a position in Castle Biosciences in Q2 2023 and has held it in 13 quarters since.
  • Harbor Capital Advisors's Castle Biosciences position peaked at $4.39M in Q3 2024.
  • 77 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Harbor Capital Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.